A PHASE 3 trial has demonstrated that tavapadon significantly improves motor symptoms in people with early Parkinson’s disease, positioning Tavapadon as a promising option for patients in the early stages of disease.
Tavapadon
Tavapadon is a selective dopamine D1 and D5 receptor agonist designed to improve motor control, whilst avoiding the adverse effects linked to traditional dopaminergic therapies. Its development reflects the need for effective early interventions in Parkinson’s disease that can provide symptom relief with improved safety.
Methods and Results of the Trial
The TEMPO 1 study was a phase 3, double blind, placebo-controlled randomised clinical trial conducted at 102 sites across 12 countries between December 2019 and June 2024, with a 4-week safety follow up. Of the 751 adults screened, 529 participants with early Parkinson disease were enrolled and randomised 1:1:1 to tavapadon 5 mg n = 177, tavapadon 15 mg n = 177, or placebo n = 175 for 27 weeks.
The data showed that the change from baseline to week 26 in the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) parts II and III combined score was significantly improved in participants treated with both the 5-mg dose of tavapadon (−11.5 points; 95% CI, −13.8 to −9.2; P < .001; d = 1.14) and 15-mg dose of tavapadon (−12.1 points; 95% CI, −14.4 to −9.8; P < .001; d = 1.20). Tavapadon had a favorable safety profile, and common adverse events included nausea 25.4%, headache 16.7%, and dizziness 12.7%.
Clinical Implications for Tavapadon Use
These findings indicate tavapadon provides clinically meaningful improvements in motor function in early Parkinson’s disease, with effect sizes supporting its therapeutic relevance. The favourable safety profile, with predominantly mild to moderate adverse events, enhances its suitability for early-stage use. Future research should evaluate long-term outcomes, disease progression effects, and comparative effectiveness against existing treatments. Broader real-world data will be important to confirm generalisability and optimise treatment strategies involving tavapadon in routine clinical practice.
Reference
Pahwa R et al. Fixed-dose tavapadon for early parkinson disease: a randomized clinical Trial. JAMA Neurol. 2026;DOI:10.1001/jamaneurol.2026.0590.
Features image: onephoto on Adobe Stock
